Evidence map›Paper›PMID 35571124›Full record

ArticleFrontiers in pharmacology2022

Corrigendum: Diplatin, a Novel and Low-Toxicity Anti-Lung Cancer Platinum Complex, Activation of Cell Death in Tumors

Xixi Lin, Yongliang Jia, Xinwei Dong, Jian Shen, Yachao Jin, Yanyou Li, Fang Wang, Eitan Anenberg, Jiancang Zhou, Jianping Zhu and 3 more

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Xixi LinChildren's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yongliang JiaZhejiang Respiratory Drugs Research Laboratory of Food and Drug Administration of China, Zhejiang University School of Medicine, Hangzhou, China.
Xinwei DongZhejiang Respiratory Drugs Research Laboratory of Food and Drug Administration of China, Zhejiang University School of Medicine, Hangzhou, China.
Jian ShenZhejiang Respiratory Drugs Research Laboratory of Food and Drug Administration of China, Zhejiang University School of Medicine, Hangzhou, China.
Yachao JinBreath Smooth Biotech Hangzhou Co., LTD, Hangzhou, China.
Yanyou LiBeijing Shuobai Pharmaceutical Co., LTD, Beijing, China.
Fang WangJoinn Laboratories, BAD, Beijing, China.
Eitan AnenbergChildren's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jiancang ZhouSir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jianping ZhuSir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xiaoping ChenBeijing Shuobai Pharmaceutical Co., LTD, Beijing, China.
Qiangmin XieChildren's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yicheng XieChildren's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zhejiang University · CNChildren's Hospital of Zhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fphar.2019.00982.].

Indexed as

cisplatin resistancelung cancerPlatinum complexROS/p53 pathwayWater solubility

Identifiers

PMID35571124
PMCPMC9097790
OpenAlexW4286843100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.